Drug Trial Radar · NCT06672718
A Study of SPY002-091 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Nov 26, 2024
Primary completion
Aug 19, 2026
Study completion Aug 19, 2026
Sponsor
- Lead sponsor
- Spyre Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Altasciences Company Inc.
- First posted
- Nov 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, randomized, double-blind, placebo-controlled, single- dose, first in human safety, tolerability, and pharmacokinetic study of SPY002-091 in healthy participants.
Conditions
- Healthy
Interventions
SPY002-091Drug
Experimental
PlaceboOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment emergent adverse eventsTime frame: Up to 40 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Spyre Site 1
Cypress, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.